Health Canada’s safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors — e.g., Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin) — concluded in July 2018 with the finding that there may be a link between the use of SGLT2 inhibitors and acute pancreatitis. However there was limited evidence to suggest a link with chronic pancreatitis. Health Canada is working with the manufacturers to update the Canadian product monographs, or drug labels, for SGLT2 inhibitors to include this increased risk of pancreatitis.
The post Invokana / Jardiance / Farxiga: Increased Risk Of Pancreatitis, According To Health Canada Safety Review appeared first on Law Offices of Thomas J. Lamb.